P1VITAL PRODUCTS LIMITED

Their core work

P1Vital is a UK neuroscience SME working on clinical stratification and treatment-response prediction in psychiatric disorders — principally depression, schizophrenia and Alzheimer's disease. Their H2020 footprint centres on cognitive and behavioural biomarkers used to decide which patients are likely to respond to which treatment, delivered inside large pharma-academic clinical consortia. In recent work they have pushed toward transdiagnostic and digital biomarkers, bringing quantitative, measurable endpoints into trials that historically relied on subjective psychiatric ratings. They are the kind of partner a consortium pulls in when cognitive testing, clinical trial measurement and psychiatric data analysis have to actually work in patients.

What they specialise in

How they've shifted over time

The 2015-2019 work was anchored in a single disease area — predicting response to depression treatment (PReDicT) and early stratification in PRISM. From 2021 onward (PRISM 2), the focus broadens into transdiagnostic and translational neuroscience, pulling in Alzheimer's and schizophrenia alongside depression, and explicitly adding digital biomarkers and quantitative biology. The trajectory is from drug-response prediction toward a multi-disorder, data-driven biomarker platform.

They are moving from single-disease (depression) response prediction toward a cross-disorder digital biomarker platform, which makes them relevant to any new consortium combining psychiatry, AI/data and clinical measurement.

How they like to work

P1Vital joins as a third-party specialist rather than leading, plugging into large pharma-led consortia (IMI2 PRISM, PRISM 2) and SME-phase clinical projects (PReDicT). Across 3 projects they worked with 29 distinct partners across 9 countries, which signals they are a trusted satellite expert rather than a hub — brought in for a specific capability (cognitive testing, clinical measurement) rather than to run the programme.

Worked with 29 unique partners across 9 countries, all within European pharma/academic psychiatry networks anchored by the IMI programme. No evidence of activity outside the European R&D sphere.

What sets them apart

P1Vital is one of very few European SMEs whose entire research identity sits at the intersection of clinical psychiatry, cognitive testing and biomarker stratification — not a generic CRO and not an academic lab. They are the kind of partner pharma consortia bring in when they need validated cognitive assessments and treatment-response modelling inside a real trial, rather than methodological theory. Their presence across both IMI2 PRISM generations shows continued trust from the pharma side.

Highlights from their portfolio

• PReDicT
  SME-phase project directly matching P1Vital's commercial core — predicting antidepressant response, which is the kind of clinical decision-support product the company sells.
• PRISM 2
  Recent IMI2 follow-on (2021-2024) that expands stratification beyond depression into Alzheimer's and schizophrenia, and introduces digital biomarkers — the clearest signal of where they are heading.
• PRISM
  Large IMI2 pharma consortium (Sofia ref. 115916) that established P1Vital inside Europe's public-private psychiatry biomarker initiative.